Ocrelizumab

Important lines of research in progressive multiple sclerosis 2:54
Important lines of research in progressive multiple sclerosis
Lawrence Steinman • 11 Apr 2022
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab 1:12
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab
Lilyana Amezcua • 4 Apr 2022
Updates on natalizumab and anti-CD20 antibodies for MS 2:21
Updates on natalizumab and anti-CD20 antibodies for MS
Massimo Filippi • 26 Jun 2022
Personalized B-cell tailored dosing of ocrelizumab in MS 0:56
Personalized B-cell tailored dosing of ocrelizumab in MS
Alyssa Toorop • 26 Jun 2022
Deep learning can predict treatment response in patients with progressive MS 8:41
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet • 22 Mar 2022
Managing MS relapses during pregnancy 2:25
Managing MS relapses during pregnancy
Kristen Krysko • 4 Apr 2022
Progressive MS treatment – what is next? 1:39
Progressive MS treatment – what is next?
Giancarlo Comi • 23 Mar 2022
Using DMTs beyond patients with active MS 3:14
Using DMTs beyond patients with active MS
Xavier Montalban • 29 Mar 2022
Differential efficacy of DMTs in patients with active and inactive MS 1:30
Differential efficacy of DMTs in patients with active and inactive MS
Xavier Montalban • 29 Mar 2022
Changes in the MS treatment landscape over the last 2 years 6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri • 22 Mar 2022
Real-world studies of CGRP monoclonal antibodies and gepants for migraine 5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang • 3 Apr 2022
Selecting treatment options for NMOSD 1:51
Selecting treatment options for NMOSD
Michael Levy • 3 Apr 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab 3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana • 28 Feb 2022
Impact of ocrelizumab disruption on RRMS 2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett • 25 Feb 2022
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS 2:07
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS
Namita Tundia • 25 Feb 2022
The content of VJNeurology is intended for healthcare professionals